Cargando…
Noncompetitive inhibition of human CYP2C9 in vitro by a commercial Rhodiola rosea product
A commercial Rhodiola rosea (R. rosea) product has previously demonstrated CYP2C9 inhibition in humans. The purpose of this study was to provide in vitro inhibitory data for this particular interaction and to classify the mechanism of the interaction. Another aim was to examine the in vitro influenc...
Autores principales: | Thu, Ole Kristian Forstrønen, Spigset, Olav, Hellum, Bent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684854/ https://www.ncbi.nlm.nih.gov/pubmed/28805981 http://dx.doi.org/10.1002/prp2.324 |
Ejemplares similares
-
Rhodiola rosea: A Therapeutic Candidate on Cardiovascular Diseases
por: Chen, Yingqing, et al.
Publicado: (2022) -
Rhodiola rosea Reduces Intercellular Signaling in Campylobacter jejuni
por: Kunčič, Ajda, et al.
Publicado: (2022) -
A supercritical fluid workflow for the quality assessment of herbal drugs and commercial preparations from
Rhodiola rosea
por: Langeder, Julia, et al.
Publicado: (2021) -
Chemical Composition, Antioxidant and Anti-Enzymatic Activity of Golden Root (Rhodiola rosea L.) Commercial Samples
por: Polumackanycz, Milena, et al.
Publicado: (2022) -
Rhodiola rosea for physical and mental fatigue: a systematic review
por: Ishaque, Sana, et al.
Publicado: (2012)